Understand the source comparison
ARA-290 vs VIP: Research Applications Comparison
Peripheral Neuropathy Models Phase 2 clinical data showing 42% pain reduction in sarcoidosis-associated small fiber neuropathy; accelerates remyelination in sciatic nerve injury models No clinical trial data for peripheral neuropathy; short half-life (60–90 se
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Peripheral Neuropathy Models
- Phase 2 clinical data showing 42% pain reduction in sarcoidosis-associated small fiber neuropathy; accelerates remyelination in sciatic nerve injury models
- No clinical trial data for peripheral neuropathy; short half-life (60–90 seconds) requires continuous infusion
- ARA-290 is the evidence-backed choice for peripheral nerve studies with practical dosing advantages
- Autoimmune Disease Research
- Suppresses NF-κB in immune cells but doesn't shift T-cell differentiation or promote Tregs
- Inhibits Th1/Th17 responses, promotes regulatory T-cells, demonstrated 40% mortality reduction in sepsis models
- VIP's systemic immunomodulatory profile makes it superior for autoimmune and inflammatory research
- Ischemia-Reperfusion Injury
- Activates tissue-protective JAK2/STAT3 and PI3K/Akt pathways in cardiac, renal, and neural tissues; reduces apoptosis
- VPAC receptor activation improves vasodilation but lacks direct cellular anti-apoptotic signaling
- ARA-290's direct tissue-protective receptor pathway delivers stronger cytoprotection in ischemic models
- Neuroinflammation Studies
- Reduces cytokine production secondarily through tissue-protective signaling
- Primary mechanism suppresses microglial activation and pro-inflammatory cytokine release (IL-1β, TNF-α)
- VIP is the primary tool for neuroinflammation research where microglial modulation is the endpoint
- Practical Dosing Feasibility
- Half-life 4–6 hours allows intermittent dosing; subcutaneous administration
- Half-life 60–90 seconds requires continuous infusion or frequent injections; rapid enzymatic degradation
- ARA-290's longer half-life and dosing flexibility reduce protocol complexity in multi-week studies
- Tissue Selectivity
- CD131 receptor expression concentrated in neural, cardiac, renal, vascular tissues. Minimal bone marrow presence
- VPAC1/VPAC2 expressed broadly across immune cells, neurons, smooth muscle, epithelial tissues
- ARA-290 for localized tissue protection; VIP for systemic immune or multi-organ effects